Slides
Page 1
High organic sales growth and stronger margins despite geopolitical headwinds Getinge Q3 2025 Mattias Perjos, CEO Agneta Palmér, CFO
Page 2
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs October 21, 2025 Getinge │ Presentation │ Q3 Report 2025 Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales 1,9 1,1 2023 R12 Sep 2025 -42% 61% Q3 2022 Q3 2023 Q3 2024 65% Q3 2025 Capital goods Recurring revenue 62% Q3 2022 Q3 2023 Q3 2024 68% Q3 2025 Rest of Portfolio High margin products Sales share in R12 figures. 1) Defined as products with adjusted gross margin higher than its Business Area in 2024; 2) Net debt/adj. EBITDA < 2.5; 3) ROIC at least > Weighted Average Cost of Capital Improvements should be achieved through balanced leverage2 and attractive long-term Return on Invested Capital3
Page 3
Key takeaways Q3 2025 Getinge │ Presentation │ Q3 Report 2025 • Net sales grew by 9.5% organically and order intake increased by 4.7% organically • Margins positively impacted by acquisitions, price, mix and productivity • The financial position remains solid 50 55 Q3 2024 Q4 2024 Q1 2025 Q2 2025 50.7 Q3 2025 0 14 15 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 14.5 R12 Gross Margin (adj) % R12 EBITA Margin (adj) % 0 34,000 35,000 36,000 Q3 2024 Q4 2024 Q1 2025 Q2 2025 35,854 Q3 2025 R12M Net Sales, SEK M October 21, 2025
Page 4
Offering and customers • Getinge’s T-DOC provides the software intelligence in Sweden’s first fully automated Central Sterile Supply Department at Malmö University Hospital. • Getinge Manufacturing Excellence has realized lead time reduction in Life Science for some products in category WIS by more than 20% and COGS by about 10%. • Partnership with Philips to offer hospitals in CE markets an integrated anesthesia workstation for the operating room. Sustainability and Quality • CE Mark reinstated for Getinge’s Cardiosave Intra-Aortic Balloon Pump. The reinstatement is subject to certain conditions, which Getinge is committed to fulfilling. • EU MDR approval of further indications for our V12 balloon expandable covered stents. The approval of three different indicators (BEVAR, FEVAR and IBD) represents a key enabler for growth in the European endovascular market. • CO2 emissions continue to decrease. Key activities and events Q3 2025 October 21, 2025 Getinge │ Presentation │ Q3 Report 2025
Page 5
Order Intake and Net Sales Bridge Q3 2024 – Q3 2025 Solid organic Net Sales growth in all Business Areas and regions 137 168 8,486 Q3 2024 Acute Care Therapies Life Science Surgical Workflows 8,477 Q3 2025 SEK M -314 -0.1% +6.5% +21.9% -3.6% Organic change +4.7% 317 94 7,870 Q3 2024 Acute Care Therapies Life Science -56 Surgical Workflows 8,226 Q3 2025 SEK M +4.5% +11.4% +15.9% +4.7% +9.5% Organic change Order Intake Net Sales Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 6
Adjusted Gross Profit and EBITA Bridge Q3 2024 – Q3 2025 Margins increased in the quarter despite headwinds from tariffs and FX 251 15 3,799 Q3 2024 Acute Care Therapies Life Science -14 Surgical Workflows 4,051 Q3 2025 SEK M +6.6% Adj GM, % Q3 2025 (Q3 2024) Gross Margin impact Currency Product and Geo mix Cost (incl. tariffs) Price 903 252 16 18 Q3 2024 Adj GP -14 Adj Selling -35 Adj Admin Adj R&D -61 Other OPEX D&A 1,079 Q3 2025 SEK M +19.5% 56.6 36.5 42.8 49.2 (38.5) (42.5) (48.3)(54.8) 11.5% 13.1% +1.4 pp Adj GP +0.2 pp Adj OPEX +0.6 pp D&A -0.6 pp FX Adjusted Gross Profit Adjusted EBITA Margin development Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 7
Tariffs having a material impact on adjusted EBITA Impact from tariffs October 21, 2025 Getinge │ Presentation │ Q3 Report 2025 Reminder from the Q1 presentation Impact on adj EBITA in Q3 2025 -108 MSEK Approx Impact on adj EBITA YTD 2025 -218 MSEK Approx
Page 8
But efforts to mitigate negative impact from tariffs are clearly working Impact on margin from tariffs and FX October 21, 2025 Getinge │ Presentation │ Q3 Report 2025 13,1 11,5 14,4 14,9 Q3 2024 Q3 2025 Reported adj EBITA margin Excl tariffs Excl FX and tariffs Q3 2024 vs Q3 2025 Reminder from the Q2 presentation Illustrative view on adj EBITA margin excl tariffs and FX in Restatement: With current tariff levels, Getinge expects to reach the target of >12% average annual growth in adjusted EPS 2024-2028
Page 9
Getinge has a solid financial position Improved FCF Y-o-Y and good safety margin on leverage despite significant acquisition FCF positively impacted by improved operating profit… 0.4 Q3 2024 1.7 Q4 2024 0.2 Q1 2025 0.5 Q2 2025 Q3 2025 0.8 Free Cash Flow, SEK B … and leverage continues to be well below 2.5x 2.0 Q3 2024 1.6 Q4 2024 1.4 Q1 2025 1.7 Q2 2025 2.0 1.6 1.4 1.7 Q3 2025 1.6 1.6 Net debt/Adj EBITDA R12 (1.2x excl. pension liabilities) Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 10
Net sales for 2025 expected to increase by 2-5% organically Outlook 2025 Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 11
Summary Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 12
Key takeaways Summary Q3 2025 • Strong performance in the quarter with solid organic growth • Improved margins despite tariffs and negative FX • The financial position remains solid • Outlook for 2025: organic net sales growth of 2-5% Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 13
Q&A Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 14
Thank you Getinge │ Presentation │ Q3 Report 2025 October 21, 2025
Page 15
This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates. Forward looking information Getinge │ Presentation │ Q3 Report 2025 October 21, 2025